Launch of OptiMAL platform
Fusion Antibodies plc has officially launched its OptiMAL® platform for discovering novel human antibodies, incorporating a proprietary synthetic library and Mammalian Display technology, with the library and its design method protected by US patent no. US12378696 and pending international patents. This launch, presented at the Antibody Engineering and Therapeutics conference, signifies a key development for the company's pre-clinical antibody discovery and engineering services, aiming to accelerate the delivery of therapeutic antibodies to market.
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the official launch of the OptiMAL® platform for the discovery of novel human antibodies. The OptiMAL® platform incorporates the Company's naïve, synthetic library of antibody sequences and the Mammalian Display used to select individual antibodies from the Library against a target of interest. As has been previously announced by the Company, the OptiMAL® library and the method for designing the Library are protected under US patent no. US12378696 and patents pending in other territories.
The official launch of the OptiMAL® platform took place at the Antibody Engineering and Therapeutics conference in San Diego with a speaker presentation by Dr. Richard Buick, CSO, followed by poster presentations and an exhibit booth. CEO Adrian Kinkaid also attended the official launch of OptiMAL®.
Richard Buick, CSO of Fusion, said: "I am delighted to see the culmination of several years' work presented to an audience of antibody industry peers and look forward to the future of using this technology to bring more human therapeutic antibodies to the market."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.